Top line for Merck's vorapaxar: a bleeding concern but still some hope
This article was originally published in Scrip
Executive Summary
Merck & Co's protease activated receptor 1 (PRA) inhibitor vorapaxar has met its primary endpoint in the Phase III ischaemia TRA-2P study, but this came at the expense of a significant increase in bleeding, top-line data show.